Bernabe Ignacio Bustos

Bernabe Ignacio Bustos

Auto-generated profile, based on publicly available information

Bernabe Ignacio Bustos

Ken and Ruth Davee Department of Neurology and Simpson Querrey Center for Neurogenetics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2014 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
GFGiancarlo Ferrari
Giancarlo Ferrari
MAMiguel E. Avila
Miguel E. Avila
MMMatias A. Medina
Matias A. Medina
EPEduardo Perez-Palma
Eduardo Perez-Palma
BBBernabe I. Bustos
Bernabe I. Bustos
Marcelo AlarcónMarcelo Alarcón
Marcelo Alarcón
Alzheimer’s disease is a neurodegenerative disorder that causes a progressive decline of mental and cognitive processes such as memory, judgment and reasoning. We proposed earlier that a sustained loss of function of Wnt/β- catenin signaling components underlies the onset and progression of the disease. Here, we discuss recent data on the involvement of Wnt/b-catenin signaling on amyloid precursor protein (APP) processing, Aβ peptide neurotoxicity, τ phosphorylation, and modulation of Apolipoprotein E function in the brain. We conclude that several components of the cascade are actively engaged in the events leading to AD neuropathology and propose that compounds that mimic activation of this signaling cascade, such as lithium, should be considered for therapeutic intervention in Alzheimer's patients. In summary, data accumulated during the past decade confirm some important predictions of our hypothesis where components of this signaling cascade are actively engaged in the events leading to AD neuropathology and that compounds that mimic activation of this signaling cascade, such as lithium, should be considered for therapeutic intervention in Alzheimer's patients.

1 January 2021 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
SLSteven J Lubbe
Steven J Lubbe
BBBernabe I Bustos
Bernabe I Bustos
JHJing Hu
Jing Hu
DKDimitri Krainc
Dimitri Krainc
TJTheresita Joseph
Theresita Joseph
F(for International Parkinson’s Disease Genomics Consortium (IPDGC)
for International Parkinson’s Disease Genomics Consortium (IPDGC)
Biallelic Parkin (PRKN) mutations cause autosomal recessive Parkinson’s disease (PD); however, the role of monoallelic PRKN mutations as a risk factor for PD remains unclear. We investigated the role of single heterozygous PRKN mutations in three large independent case-control cohorts totalling 10 858 PD cases and 8328 controls. Overall, after exclusion of biallelic carriers, single PRKN mutations were more common in PD than controls conferring a >1.5-fold increase in the risk of PD [P-value (P) = 0.035], with meta-analysis (19 574 PD cases and 468 488 controls) confirming increased risk [Odds ratio (OR) = 1.65, P = 3.69E-07]. Carriers were shown to have significantly younger ages at the onset compared with non-carriers (NeuroX: 56.4 vs. 61.4 years; exome: 38.5 vs. 43.1 years). Stratifying by mutation type, we provide preliminary evidence for a more pathogenic risk profile for single PRKN copy number variant (CNV) carriers compared with single nucleotide variant carriers. Studies that did not assess biallelic PRKN mutations or consist of predominantly early-onset cases may be biasing these estimates, and removal of these resulted in a loss of association (OR = 1.23, P = 0.614; n = 4). Importantly, when we looked for additional CNVs in 30% of PD cases with apparent monoallellic PRKN mutations, we found that 44% had biallelic mutations, suggesting that previous estimates may be influenced by cryptic biallelic mutation status. While this study supports the association of single PRKN mutations with PD, it highlights confounding effects; therefore, caution is needed when interpreting current risk estimates. Together, we demonstrate that comprehensive assessment of biallelic mutation status is essential when elucidating PD risk associated with monoallelic PRKN mutations.

22 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EPEduardo Pérez-Palma
Eduardo Pérez-Palma
BBBernabé I. Bustos
Bernabé I. Bustos
CVCamilo F. Villamán
Camilo F. Villamán
Marcelo AlarcónMarcelo Alarcón
Marcelo Alarcón
MAMiguel E. Avila
Miguel E. Avila
TGthe NIA-LOAD/NCRAD Family Study Group
the NIA-LOAD/NCRAD Family Study Group
Genome-wide association studies (GWAS) have successfully identified several risk loci for Alzheimer's disease (AD). Nonetheless, these loci do not explain the entire susceptibility of the disease, suggesting that other genetic contributions remain to be identified. Here, we performed a meta-analysis combining data of 4,569 individuals (2,540 cases and 2,029 healthy controls) derived from three publicly available GWAS in AD and replicated a broad genomic region (>248,000 bp) associated with the disease near the APOE/TOMM40 locus in chromosome 19. To detect minor effect size contributions that could help to explain the remaining genetic risk, we conducted network-based pathway analyses either by extracting gene-wise p-values (GW), defined as the single strongest association signal within a gene, or calculated a more stringent gene-based association p-value using the extended Simes (GATES) procedure. Comparison of these strategies revealed that ontological sub-networks (SNs) involved in glutamate signaling were significantly overrepresented in AD (p<2.7×10−11, p<1.9×10−11; GW and GATES, respectively). Notably, glutamate signaling SNs were also found to be significantly overrepresented (p<5.1×10−8) in the Alzheimer's disease Neuroimaging Initiative (ADNI) study, which was used as a targeted replication sample. Interestingly, components of the glutamate signaling SNs are coordinately expressed in disease-related tissues, which are tightly related to known pathological hallmarks of AD. Our findings suggest that genetic variation within glutamate signaling contributes to the remaining genetic risk of AD and support the notion that functional biological networks should be targeted in future therapies aimed to prevent or treat this devastating neurological disorder.

1 June 2013 in Neurobiology of Aging
Verified
Journal Article
Closed access
Marcelo AlarcónMarcelo Alarcón
Marcelo Alarcón
MMMatías A. Medina
Matías A. Medina
QHQubai Hu
Qubai Hu
MAMiguel E. Avila
Miguel E. Avila
BBBernabé I. Bustos
Bernabé I. Bustos
GFGiancarlo V. De Ferrari
Giancarlo V. De Ferrari

9 November 2022 in Brain
Verified
Journal Article
Closed access
PDF file
BBBernabe I Bustos
Bernabe I Bustos
KBKimberley Billingsley
Kimberley Billingsley
CBCornelis Blauwendraat
Cornelis Blauwendraat
JGJ Raphael Gibbs
J Raphael Gibbs
ZGZiv Gan-Or
Ziv Gan-Or
I(International Parkinson’s Disease Genomics Consortium (IPDGC)
International Parkinson’s Disease Genomics Consortium (IPDGC)
Parkinson’s disease is a complex neurodegenerative disorder with a strong genetic component, for which most known disease-associated variants are single nucleotide polymorphisms (SNPs) and small insertions and deletions (indels). DNA repetitive elements account for >50% of the human genome; however, little is known of their contribution to Parkinson’s disease aetiology. While select short tandem repeats (STRs) within candidate genes have been studied in Parkinson’s disease, their genome-wide contribution remains unknown. Here we present the first genome-wide association study of STRs in Parkinson’s disease. Through a meta-analysis of 16 imputed genome-wide association study cohorts from the International Parkinson’s Disease Genomic Consortium (IPDGC), totalling 39 087 individuals (16 642 cases and 22 445 controls of European ancestry), we identified 34 genome-wide significant STR loci (P < 5.34 × 10−6), with the strongest signal located in KANSL1 [chr17:44 205 351:[T]11, P = 3 × 10−39, odds ratio = 1.31 (95% confidence interval = 1.26–1.36)]. Conditional-joint analyses suggested that four significant STRs mapping nearby NDUFAF2, TRIML2, MIRNA-129–1 and NCOR1 were independent from known risk SNPs. Including STRs in heritability estimates increased the variance explained by SNPs alone. Gene expression analysis of STRs (eSTRs) in RNA sequencing data from 13 brain regions identified significant associations of STRs influencing the expression of multiple genes, including known Parkinson’s disease genes. Further functional annotation of candidate STRs revealed that significant eSTRs within NUDFAF2 and ZSWIM7 overlap with regulatory features and are associated with change in the expression levels of nearby genes. Here, we show that STRs at known and novel candidate loci contribute to Parkinson’s disease risk and have functional effects in disease-relevant tissues and pathways, supporting previously reported disease-associated genes and giving further evidence for their functional prioritization. These data represent a valuable resource for researchers currently dissecting Parkinson’s disease risk loci.

9 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LZLinda Zollner
Linda Zollner
FBFelix Boekstegers
Felix Boekstegers
CPCarol Barahona Ponce
Carol Barahona Ponce
Dominique SchererDominique Scherer
Dominique Scherer
KMKatherine Marcelain
Katherine Marcelain
Justo Lorenzo BermejoJusto Lorenzo Bermejo
Justo Lorenzo Bermejo
A strong association between the proportion of indigenous South American Mapuche ancestry and the risk of gallbladder cancer (GBC) has been reported in observational studies. Chileans show the highest incidence of GBC worldwide, and the Mapuche are the largest indigenous people in Chile. We set out to assess the confounding-free effect of the individual proportion of Mapuche ancestry on GBC risk and to investigate the mediating effects of gallstone disease and body mass index (BMI) on this association. Genetic markers of Mapuche ancestry were selected based on the informativeness for assignment measure, and then used as instrumental variables in two-sample Mendelian randomization analyses and complementary sensitivity analyses. Results suggested a putatively causal effect of Mapuche ancestry on GBC risk (inverse variance-weighted (IVW) risk increase of 0.8% per 1% increase in Mapuche ancestry proportion, 95% CI 0.4% to 1.2%, p = 6.7 × 10−5) and also on gallstone disease (3.6% IVW risk increase, 95% CI 3.1% to 4.0%), pointing to a mediating effect of gallstones on the association between Mapuche ancestry and GBC. In contrast, the proportion of Mapuche ancestry showed a negative effect on BMI (IVW estimate −0.006 kg/m2, 95% CI −0.009 to −0.003). The results presented here may have significant implications for GBC prevention and are important for future admixture mapping studies. Given that the association between the individual proportion of Mapuche ancestry and GBC risk previously noted in observational studies appears to be free of confounding, primary and secondary prevention strategies that consider genetic ancestry could be particularly efficient.